Preliminary Results

RNS Number : 0568Y

Provexis PLC

04 September 2015

4 September 2015 Provexis plc

("Provexis" or the "Company")

PRELIMINARY RESULTS for the YEAR ended 31 MARCH 2015

Provexis plc ("Provexis" or the "Company"), the business that develops and licenses the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its audited preliminary results for the year ended 31 March 2015.

Key highlights

· Significantly enhanced financial terms agreed for the Company's long-term Alliance Agreement with DSM for Fruitflow®, backdated to 1 January 2015, increasing the ongoing profit share payable to the Company.

· Over 40 regional consumer healthcare brands containing Fruitflow® now launched by DSM's customers; DSM's total revenues for Fruitflow® for the year ended 31 March 2015 grew strongly by more than 73% year on year, reflecting strong interest in the product and the success of the powder format.

· An increasing number of further commercial projects have been initiated by DSM with prospective customers, including some prospective customers which are part of global businesses.

· A new product video for Fruitflow® was produced in the year, and it has been viewed by a wide variety of current and prospective customers, Fruitflow® has also been promoted at several major trade shows.

· Company is in the process of submitting some of the underlying scientific studies for Fruitflow® for publication in scientific journals, publication is expected to be a significant opportunity to promote Fruitflow® more widely.

· Collaboration agreement with the University of Oslo signed in November 2014 to undertake further research into the relationship between Fruitflow® and blood pressure regulation. Encouraging key results released in June 2015 covering stage one of this two stage agreement, strong evidence from the laboratory based work that a standard dose of Fruitflow® has the potential to give a clinically relevant reduction in systolic blood pressure. Ethics approval granted for the stage two small clinical trial which will commence shortly.

· Company is in the process of launching a high quality dietary supplement product containing Fruitflow® and Omega-3 which will be sold initially from the Company's website; expected to provide an additional income and profit stream.

· Company joined the online equity crowdfunding platform PrimaryBid.com in June 2015, and raised a net £267k through the platform in July 2015.

Key financial results

· Revenues from profit sharing Alliance for the period £38k (2014: £4k);

· Underlying operating loss from continuing operations* reduced to £0.41m (2014: £0.58m), a record low for the Group, reflecting increasing revenues set against the Group's low overhead licensing business model.

· Statutory operating loss from continuing operations £0.50m (2014: £1.02m); statutory loss attributable to owners of the parent £0.44m (2014: profit of £0.49m). These results are after charging £Nil (2014: £0.05m) of demerger costs, and a £0.09m (2014: £0.39m) non-cash share based payment charge.

· Cash balance at 31 March 2015 £0.29m (2014: £0.51m), net cash of £0.27m raised in July 2015, after the year end, through PrimaryBid.com.

· Basic loss per share from continuing operations 0.03p (2014: 0.06p).

*before demerger costs of £Nil (2014: £0.05m) and share based payments of £0.09m (2014: £0.39m), as set out on the face of the Consolidated Statement of Comprehensive Income

For further information please contact:

Provexis plc Tel: 07917 670260

Dawson Buck, Chairman enquiries@provexis.com

Ian Ford, Finance Director

Cenkos Securities plc Tel: 020 7397 8900

Bobbie Hilliam

Chairman's statement

The Company has had another strong year of progress, building on the low overhead strategy for the business which was adopted in 2013.

The Company's Alliance partner DSM Nutritional Products has continued to develop the market actively for the Company's novel, patented Fruitflow® heart-health ingredient in all global markets, with over 40 regional consumer healthcare brands now having been launched by DSM customers. DSM's total revenues for Fruitflow® for the year ended 31 March 2015, which are denominated in Euros, grew strongly by more than 73% year on year, reflecting strong interest in Fruitflow® and the success of the powder format which is being used in an increasing number of new product launches.

In June 2015 the Company announced that it had agreed significantly enhanced financial terms for its long-term Alliance Agreement with DSM for Fruitflow®, backdated to 1 January 2015, which will have a significant positive effect on the Company's ongoing profit share from the Alliance.

Revenues from the profit sharing Alliance for the year were £38k, compared to £4k in the prior year, and the underlying operating loss from continuing operations was reduced by 29% year on year to £0.41m, a record low for the Group, reflecting increasing revenues set against the Group's low overhead licensing business model.

Fruitflow®

The Company's Alliance partner DSM Nutritional Products has continued to make good progress marketing Fruitflow®, with more than 13 new consumer brands having been launched by DSM customers in the year.

An increasing number of further commercial projects have been initiated by DSM with prospective customers, including some prospective customers which are part of global businesses, with good prospects for these projects to be launched as consumer products. Interest in the technology exists in all major global markets.

The powder format of Fruitflow® which was launched in 2013 has broad potential applications in tablet, gel capsule and dietary supplement products, and interest from potential customers for this format remains strong.

The Company's Alliance Agreement with DSM Nutritional Products for Fruitflow® includes a financial model which is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales. In June 2015 the Company announced that it had agreed significantly enhanced financial terms for the Alliance Agreement with DSM, under which the fixed level of overhead deduction from sales permanently decreased with effect from 1 January 2015, backdated, thus increasing the ongoing profit share payable to the Company.

If the revised fixed level of overhead deduction from sales had been in place from the inception of the Agreement in June 2010, the underlying profit share payable to the Company in Euros would have been 101% higher than the actual profit share that was payable to the Company over the three and a half year period ended 30 September 2014.

The Company stated in its interim results in December 2014 that the fixed level of overhead deduction from sales in the Alliance Agreement was set to decrease contractually from 1 January 2016, but the decrease announced in June 2015 exceeds the decrease which had been envisaged, to the Company's advantage, and consequently the 1 January 2016 change will not take effect.

The revised commercial terms of the Alliance Agreement reflect the continued strength of the long term relationship between Provexis and DSM. All other commercial terms of the Alliance Agreement remain confidential between the two parties.

DSM has invested substantial resource into establishing a commercial scale supply chain for powder manufacturing and cost of goods were initially high in this start-up phase, on a low volume base, which is typical for a new ingredient launch. DSM's manufacturing and technical teams have been highly focused on reducing Fruitflow® production costs and as manufacturing volume increases unit costs will decrease, enabling more positive margins to the expected commercial benefit of Fruitflow® and the Provexis business.

The initial powder manufacturing setup phase for Fruitflow® was concluded in the quarter ended 30 June 2014, resulting in a significant reduction in production costs. A further significant cost reduction was identified in late 2014, and this started to take effect in the first calendar quarter of 2015. Further cost reductions will continue to be sought across all aspects of the supply chain and manufacturing process.

Marketing efforts for Fruitflow® have seen the product being promoted at several major trade shows. The product has been featured in numerous publications and it has been the subject of several trade seminars and presentations, some of which are available to view in the news section of the Company's website www.provexis.com.

Marketing initiatives during the year have included a new DSM product video for Fruitflow® which is primarily targeted at potential business customers for Fruitflow® in the consumer healthcare sector. The video makes reference to the US Food and Drug Administration's guidance in May 2014 concerning the use of low dose Aspirin, which remains a strong opportunity for Fruitflow®.

The product video has been a good opportunity to promote Fruitflow® more widely, and it has been viewed by a wide variety of current and prospective customers for Fruitflow®, with further bespoke versions of the video likely to be released in due course. The video is available to view via the Company's website www.provexis.com.

The Company is in the process of submitting some of the underlying scientific studies for Fruitflow® for publication in appropriate scientific journals, to include the Company's Aspirin Comparison Human Trial for Fruitflow®. Publication of the studies is expected to be a significant opportunity to promote Fruitflow® further.

Fruitflow® and Blood Pressure - Collaboration with University of Oslo

In November 2014 the Company signed a two stage collaboration agreement with the University of Oslo to undertake further research into the relationship between Fruitflow® and blood pressure regulation. Recent work undertaken by the University has shown that the Company's Fruitflow® technology has a potential new bioactivity, leading to blood pressure lowering effects which would be of relevance to a large number of consumers and patients with a wide range of cardiovascular conditions.

The first stage of the collaboration work has now been completed. First stage work focussed on developing the science, with major areas including fractionation, testing, bioactivity, dosage and further IP development.

The key results from this first stage have been very encouraging, with strong evidence from the laboratory based work that a standard 150mg dose of Fruitflow® in powder format has the potential to give a clinically relevant reduction in systolic blood pressure.

The Company and the University are now proceeding with the second stage of the collaboration work, which is seeing the parties conduct a small clinical trial by way of a proof of principle study. Study designs were submitted for ethics approval before finalisation, with a potential dosage for the study of 150mg Fruitflow® in powder format twice per day. The independent research ethics committee for the project has recently approved the clinical trial, which means that the proof of principle study can commence.

The University of Oslo's research team is led by Professor Asim Duttaroy, Group Leader of Chronic Disease at the Faculty of Medicine, who was the original inventor of Fruitflow®. In December 2014 we were pleased to announce that Professor Duttaroy had been re-appointed to the Company's Scientific Advisory Board.

Fruitflow® + Omega-3 dietary supplement product

The Company is in the process of launching a high quality dietary supplement product containing Fruitflow® and Omega-3 which will be sold initially from the Company's website on a mail order basis. The new dietary supplement product is expected to provide the Company with an additional income and profit stream, and the Company is seeking to minimise setup costs for this product with the use of appropriate approved outsourcers.

The final product design has been agreed and the first batch of the product has now been ordered. The Company expects to be able to have the product on sale before the end of the calendar year.

Fruitflow® and Omega-3 have separate, positive EFSA health claims and the packaging for the product will reflect these strongly. Publication of further Fruitflow® studies should give the Company a good opportunity to promote this new product on a particularly cost effective basis.

The Company is in the process of redesigning its website, in part to accommodate its new ecommerce channel, with the new website expected to be launched in the coming weeks.

Intellectual property

The Company is responsible for filing and maintaining patents and trade marks for Fruitflow® as part of the Alliance Agreement with DSM. We are pursuing a strategy to strengthen the breadth and duration of our patent coverage to maximise the commercial returns that can be achieved from the technology. Trade marks were originally registered in the larger global territories, and new registrations are typically now sought in additional territories in response to requests from current or prospective DSM customers for Fruitflow®.

In December 2013 British and international patent applications were filed for the use of Fruitflow® in mitigating exercise-induced inflammation and for promoting recovery from intense exercise, seeking to enhance further the potential of the technology in the sports nutrition sector. Patents are being sought in Europe, the US, China and ten other territories, and this patent application has now entered the national phase, with potential patent protection out to December 2033.

The Company's patent application for Fruit Extracts, relating to part of the production process for Fruitflow®, is now expected to proceed to grant in Europe in the coming months, giving patent protection out to November 2029.

Trade marks for Fruitflow® have been registered in the EU, US, China, Japan and a further nine international territories, and trade marks have been applied for in a further ten territories to support existing and forthcoming consumer brands across all major global markets.

Capital structure and funding

The Company used its equity financing facility to draw down £45k in April 2014 to strengthen the balance sheet, and help fund the Company's patent and trade mark costs for Fruitflow®. The Company raised a further £125k using its Equity Financing Facility in December 2014, which helped to fund the collaboration agreement for blood pressure regulation with the University of Oslo.

The Company is seeking to maximise the commercial returns that can be achieved from its Fruitflow® technology, and the Company's cost base and its resources continue to be very tightly managed. The Company remains keen to minimise dilution to shareholders and it is focussed on moving into profitability as Fruitflow® revenues increase, but while the Company remains in a loss making position it will need to raise working capital on occasions. Consequently in June 2015 the Company joined PrimaryBid.com (www.primarybid.com), the online platform dedicated to equity crowdfunding for AIM-listed companies, as a result of which the Company's existing 10 September 2013 equity financing agreement with Darwin Strategic Limited was cancelled. In July 2015 the Company announced that it had raised net proceeds of £267k through the new PrimaryBid.com platform.

Outlook

The Company's Alliance partner DSM Nutritional Products has continued to develop the market actively for Fruitflow® in all global markets, with over 40 regional consumer healthcare brands now having been launched by DSM customers and with strong growth in DSM's underlying sales of the product.

The significantly enhanced financial terms agreed in June 2015 with DSM for the Company's long-term Alliance Agreement for Fruitflow® will have a significant positive effect on the Company's ongoing profit share from the Alliance, and the Company will continue to maintain tight control of its cost base.

The Company and DSM are committed to a number of ongoing marketing initiatives for Fruitflow®, seeking to give the product further global exposure. The Company is seeking to maximise commercial returns from Fruitflow® and is very pleased with the encouraging results from the first stage of the Company's blood pressure collaboration with the University of Oslo, with strong evidence that a standard dose of Fruitflow® has the potential to give a clinically relevant reduction in systolic blood pressure. The Company is in the process of launching a Fruitflow® + Omega-3 dietary supplement product which will be sold initially from the Company's website, and is expected to provide the Company with an additional income and profit stream.

The past year has seen a number of very positive developments for the business, and with the Company's low operational costs we are well positioned to drive value for shareholders. We remain positive about the outlook for the business for the coming year and beyond.

Dawson Buck

Chairman

Strategic report

Group strategy

The Group strategy has historically focused on the discovery, development and commercialisation of functional foods, medical foods and dietary supplements, and in particular the Group's Fruitflow® technology.

On 1 June 2010 the Company announced that it had entered into a long term Alliance Agreement with DSM Nutritional Products to commercialise Fruitflow®, through sales as an ingredient to brand owners in the food, beverage and dietary supplement categories.

The establishment of the Alliance Agreement was a significant milestone in the history of the Company. The Alliance is seeing the partners collaborate to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications. DSM is responsible for manufacturing, marketing and selling via its substantial sales force. Provexis is responsible for contributing scientific expertise necessary for successful commercialisation, and for maintaining and strengthening the breadth and duration of its patent and trade mark coverage for Fruitflow®, seeking to maximise the commercial returns that can be achieved from the technology. Profits from the Alliance are being shared by the parties on an agreed basis, linked to various performance milestones. In June 2015 the Company confirmed that it had agreed significantly enhanced financial terms with DSM for the Company's Alliance Agreement for Fruitflow®.

The directors believed at the time of signing the Alliance Agreement, and still retain the belief, that the commercialisation of Fruitflow® is best undertaken in conjunction with DSM as it enables Provexis to leverage the resources and relationships of DSM in the major global markets.

In June 2011 the Group acquired SiS (Science in Sport) Limited, a sports nutrition business, which gave the Group two operating segments, the existing Fruitflow® business and SiS (Science in Sport) Limited.

Following a strategic review the Board concluded in June 2013 that a demerger of SiS (Science in Sport) Limited to a new AIM listed company called Science in Sport plc would be in the best interests of shareholders, as more fully detailed in a circular to shareholders and admission to trading on AIM document for Science in Sport plc which were issued on 28 June 2013. Copies of the circular and the admission to trading on AIM document can be downloaded from Provexis plc's website www.provexis.com.

The demerger of SiS (Science in Sport) Limited was effected on 9 August 2013 and Science in Sport plc was admitted to the AIM segment of the London Stock Exchangeʼs market for listed securities on that day.

Following the demerger the Group's strategic priority is to focus on developing revenues from the Fruitflow® business together with the Group's Alliance partner DSM, whilst also managing the relationship with DSM.

The Group also seeks to ensure that it fulfils its responsibilities under the Alliance Agreement to include protecting the intellectual property of Fruitflow® and assisting DSM with scientific work required to further commercialise the technology. At the same time, the Board remains committed to keeping regular and fixed costs restricted to an appropriate level, thereby maximising the Group's profit potential.

The Group continues to maintain the Crohn's disease intellectual property registered in Provexis (IBD) Limited, and it continues to investigate further options for the Crohn's disease project, seeking to maximise its value. Options currently under review include but are not limited to applications for external grant funding to progress certain aspects of the project, and ongoing discussions with prospective purchasers of the intellectual property.

Market opportunity

Fruitflow® is a patented natural extract from tomatoes which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a broad range of food, beverage and dietary supplement formats.

In May 2009, the company's Fruitflow® technology was the first to be substantiated by the European Food Safety Authority ('EFSA') under the new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim 'Helps maintain normal platelet aggregation, which contributes to healthy blood flow', which was the first wording to be authorised under Article 13(5).

The global functional food market is estimated to be in excess of $170 billion per year, and the global market for cardiovascular disease, to include dietary supplements, is estimated to be in excess of $10 billion per year. Global awareness of heart health is increasing and a rising number of people are taking a proactive approach to improving heart health. The directors believe that products addressing blood flow and circulation issues continue to represent a long-term opportunity in the expanding cardiovascular sector.

Financial review

The financial review has been prepared on the basis of Group's continuing operations, as further detailed in the consolidated statement of comprehensive income.

SiS (Science in Sport) Limited represented a separate major line of business for the Group under the definitions within IFRS 5, hence the results of SiS (Science in Sport) Limited up to the date of the demerger in August 2013 are shown as discontinued in the comparative figures for the year ended 31 March 2014 in the financial statements.

Revenue

Revenue from the profit sharing Alliance for Fruitflow® for the year ended 31 March 2015 was £37,124 (2014: £3,967).

The Company's long-term Alliance Agreement with DSM Nutritional Products for Fruitflow® includes a financial model which is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales. In June 2015 the Company confirmed that revised terms for the Alliance Agreement had been agreed with DSM, under which the fixed level of overhead deduction from sales permanently decreased with effect from 1 January 2015, backdated, thus increasing the profit share payable to the Company.

The increase in revenue accruing to the Company for the year reflects:

- An increase in DSM's underlying revenues for Fruitflow®. DSM's total revenues for Fruitflow® for the year ended 31 March 2015, which are denominated in Euros, grew by more than 73% year on year;

- A significant reduction in production costs for Fruitflow® powder, following the completion of the initial powder manufacturing setup phase for Fruitflow® in the quarter ended 30 June 2014;

- The revised terms for the Alliance Agreement under which the fixed level of overhead deduction from sales permanently decreased with effect from 1 January 2015, thus increasing the profit share payable to the Company in the quarter ended 31 March 2015.

Underlying operating loss

Underlying operating loss has reduced by 29% to £408,862 (2014: £577,961), reflecting continued progress with Fruitflow®, and the low overhead strategy adopted in 2013 which has resulted in a substantial reduction in the running costs of the business.

The Group has chosen to report underlying operating loss as the directors believe that the operating loss before demerger costs and share based payments provides additional useful information for shareholders on underlying trends and performance. A reconciliation of underlying operating loss to statutory operating loss is presented on the face of the consolidated statement of comprehensive income. This measure is used for internal performance analysis.

The Group's cost base and its resources have been and will continue to be tightly managed within budgets approved and monitored by the Board.

Research and development costs

Research and development costs have increased by 26% to £180,497 (2014: £142,985), reflecting increased expenditure on patents and trade marks for Fruitflow®, and the costs of the two stage collaboration agreement with the University of Oslo to undertake further research into the relationship between Fruitflow® and blood pressure regulation.

Taxation

A current tax credit of £5,407 (2014: £15,823), primarily in respect of research and development tax credits has been recognised in the financial statements. The tax credit claim for the year ended 31 March 2014 totalling £15,823 was paid to the Group in April 2015.

Results and dividends

The loss attributable to equity holders of the parent for the year ended 31 March 2015 was £435,598 (2014: profit of £488,353 including discontinued operations) and the basic loss per share was 0.03p (2014: profit of 0.03p). The profit attributable to equity holders of the parent for the year ended 31 March 2014 included a profit from discontinued operations of £1,434,983 (2015: £Nil) in respect of SiS (Science in Sport) Limited, which was demerged from the Group in August 2013. The profit from discontinued operations in the year ended 31 March 2014 includes the profit arising from the demerger itself, as further detailed in the Group's annual report and accounts for the year ended 31 March 2014.

The directors are unable to recommend the payment of a dividend (2014: £Nil).

Consideration of section 656 of the Companies Act 2006

On 28 August 2014 it was noted in the Company's Notice of Annual General Meeting that Section 656 of the Companies Act 2006 ('section 656') had been brought to the attention of the Directors as part of the 31 March 2014 year end accounts and audit. Section 656 states that where the net assets of a public company are half or less of its called-up share capital, the directors must call a general meeting of the company to consider whether any, and if so what, steps should be taken to deal with the situation.

It was further noted in the Company's AGM notice of 28 August 2014:

- As at 31 March 2014 the net assets of the Company were £411,302, which was less than half of the nominal value of its called-up share capital at 31 March 2014 of £1,554,816. The net assets of the consolidated Group at 31 March 2014 were £535,075.

- The annual financial statements of the Company for the year ended 31 March 2014 and the reports of the Directors thereon included a going concern statement which confirmed that the Directors had prepared projected cash flow information for a period of more than twelve months from 20 August 2014, the date of approval of the financial statements, and had reviewed this information as at 20 August 2014. The Directors had also considered this issue in light of the significant reduction in net assets following the demerger of the SiS (Science in Sport) Limited business.

- The Group's financial statements for the year ended 31 March 2014 showed that the operating costs of the Group had been substantially reduced during the year ended 31 March 2014, and in addition that the Company had access to future equity financings, either through the Company's then existing equity drawdown facility with Darwin Strategic Limited or through an equity fundraising with the Company's shareholders, as potential additional sources of funding. Based on the level of existing cash, projected income and expenditure, and excluding the potential additional sources of funding, the Directors were satisfied at 28 August 2014 that the Company and the Group had adequate resources to continue in business for the foreseeable future.

- A resolution was not put to the 2014 Annual General Meeting in connection with section 656 and it was noted that the Directors' view in August 2014 was that the most appropriate course of action was to continue to maintain tight control over the running costs of the Company and to wait for revenues from its core Fruitflow® product to increase.

Subsequent to the Company's AGM on 22 September 2014 the net assets of the Company and Group have remained less than half of the Company's called-up share capital and a further general meeting of the Company is not required under section 656.

The annual financial statements of the Company for the year ended 31 March 2015 and the reports of the Directors thereon include a going concern statement which concludes that based on the level of existing cash, projected income and expenditure, and excluding the potential additional sources of funding, the directors are satisfied that the Company and the Group have adequate resources to continue in business for a period of more than twelve months from the date of approval of the financial statements. If the potential additional sources of funding are taken into account, the directors are satisfied that the Company and the Group have adequate resources to continue in business for the foreseeable future. Accordingly the going concern basis has been used in preparing the financial statements. It remains the Directors' view on 3 September 2015 that the most appropriate course of action in respect of section 656 is to continue to seek to maximise the commercial returns that can be achieved from the Company's Fruitflow® technology, and continue to maintain very tight control over the running costs of the Company.

Capital structure and funding

On 23 April 2014 the Company announced that it had raised a net £45,403 by drawing down on the Company's Equity Financing Facility ('EFF') with Darwin Strategic Limited, allotting 7,000,000 new ordinary shares of 0.1p each to Darwin.

On 9 December 2014 the Company announced that it had raised a net £125,000 by drawing down on the Company's EFF, allotting 23,030,330 new ordinary shares of 0.1p each to Darwin.

On 4 June 2015 the Company announced that it had joined PrimaryBid.com (www.primarybid.com), an online platform dedicated to equity crowdfunding for AIM-listed companies which is further detailed in note 16; as a result of the Company joining PrimaryBid.com the Company's existing 10 September 2013 Equity Financing Facility with Darwin Strategic Limited was cancelled.

On 3 July 2015 the Group announced that it had raised net proceeds of £267,400 via the placing of 62,222,223 new ordinary shares of 0.1p each at a gross 0.45p per share ('the placing shares') with investors using the Primarybid.com platform. The placing shares were admitted to AIM on 9 July 2015.

Further details of the EFF and PrimaryBid.com agreements are available to download from the announcements section of the Company's website www.provexis.com.

Going concern

The Group's business activities together with the factors likely to affect its future development, and the financial position of the Group, its cash flows and liquidity position are set out in this strategic report. In addition note 2 to the financial statements includes the Group's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments and its exposure to credit and liquidity risk.

The Group made a loss for the year from continuing operations of £487,753 (2014: £998,264) and expects to make a further loss during the year ending 31 March 2016. The total cash outflow from continuing operations in the year was £404,776 (2014: £780,928). At 31 March 2015 the Group had cash balances of £285,403 (2014: £514,827).

On 4 June 2015 the Group announced that it had agreed significantly enhanced financial terms for its long-term Alliance Agreement with DSM, involving a reduction in the fixed level of overhead deduction from sales which permanently decreased with effect from 1 January 2015, backdated, thus increasing the profit share payable to the Company.

The directors have prepared projected cash flow information for a period of more than twelve months from the date of approval of these financial statements and have reviewed this information as at the date of these financial statements. The directors have also considered this issue in light of the significant reduction in net assets following the demerger in 2013 of the SiS (Science in Sport) Limited business.

The Group has access to future equity financings, either through the Group's existing PrimaryBid.com platform or through a separate equity fundraising with the Company's shareholders, as potential additional sources of funding.

Based on the level of existing cash, projected income and expenditure, and excluding the potential additional sources of funding, the directors are satisfied that the Company and the Group have adequate resources to continue in business for a period of more than twelve months from the date of approval of the financial statements. If the potential additional sources of funding are taken into account, the directors are satisfied that the Company and the Group have adequate resources to continue in business for the foreseeable future.

Accordingly the going concern basis has been used in preparing the financial statements.

Principal risks and uncertainties

In the course of its normal business the Group is exposed to a range of risks and uncertainties which could impact on the results of the Group. The Board considers that risk-management is an integral part of good business process and, on a bi-annual basis, reviews the industry, operational and financial risks facing the Group and considers the adequacy of the controls and mitigants to manage the risks.

The directors have identified the following principal risks and uncertainties that could have the most significant impact on the Group's long-term value generation.

Funding and other risks

Provexis has experienced operating losses from continuing operations in each year since its inception. Accordingly until Provexis has sufficient commercial success with Fruitflow® to be cash generative it will continue to rely on its existing cash resources and further funding rounds to continue its activities. While Provexis aims to generate licensing revenues from Fruitflow®, there is no certainty that such revenues will be generated. Furthermore, the amount and timing of revenues from Fruitflow® is uncertain and will depend on numerous factors, most of which are outside Provexis' control due to the terms of the Alliance Agreement. It is therefore difficult for the directors to predict with accuracy the timing and amount of any further capital that may be required by the Provexis Group.

Factors that could increase Provexis' funding requirements include, but are not limited to: higher operational costs; slower progress than expected in DSM attracting customers to purchase Fruitflow®; unexpected opportunities to develop additional products or acquire additional technologies, products or businesses; and costs incurred in relation to the protection of Provexis' intellectual property.

Any additional share issues may have a dilutive effect on Provexis Shareholders. Further, there can be no guarantee or assurance that additional equity funding will be forthcoming when required, nor as to the terms and price on which such funds would be available, nor that such funds, if raised, would be sufficient to enable Provexis to meet its working capital requirements.

Early stage of operations

Whilst the Provexis Group has generated small levels of profit share revenue from Fruitflow®, Fruitflow® is still at an early stage of its commercial development. There are a number of operational, strategic and financial risks associated with early stage companies and products. The Provexis Group faces risks frequently encountered by early stage and pre-revenue companies looking to commercialise new (food) technology. In particular, the future growth and prospects of Provexis will be heavily dependent on its alliance partner, DSM, in securing product sales on appropriate terms and to attract customers who can produce products that will maximise the revenue potential of Fruitflow®.

Provexis is heavily dependent on DSM in marketing and selling Fruitflow® to achieve market acceptance, market penetration and, ultimately, sales of products that contain Fruitflow® in sufficient commercial volumes.

The development of Provexis' revenues is difficult to predict and there is no guarantee that Provexis will generate increasing revenues in the foreseeable future. Further there can be no assurance that Provexis' proposed operations will be profitable or produce a reasonable return on investment.

Commercialisation

Due to the terms of the Alliance Agreement, Provexis is solely dependent on DSM in respect of the development, production, marketing and commercialisation of Fruitflow®. Fruitflow® is solely reliant on DSM under the terms of the Alliance Agreement for its commercialisation.

Provexis' long-term success is fully dependent on the ability of DSM to sell Fruitflow®. Provexis' negotiating position with DSM if they choose to vary the Alliance Agreement may be affected by its size and limited cash resources relative to DSM who have substantial cash resources and established levels of commercial success. An inability to enter into any discussions with DSM on equal terms could lead to reduced revenue from the Alliance Agreement and this may have a significant adverse effect on Provexis' business, financial condition and results.

The loss of, or changes affecting, Provexis' relationships with DSM could adversely affect Provexis' results or operations as Provexis has limited input on the sales strategies of Fruitflow® adopted by DSM. Furthermore, although Provexis has sought to include performance obligations on DSM in the Alliance Agreement, there is a risk that DSM may reprioritise Fruitflow® within their product portfolio resulting in Provexis achieving sales below that which it expects. Any such situation may have a material and adverse effect on Provexis' business, financial condition and results of operations.

Profitability depends on the success and market acceptance of Fruitflow®

The success of Provexis will depend on the market's acceptance and valuing of Fruitflow® and there can be no guarantee that this acceptance will be forthcoming or that Provexis' technologies will succeed. The development of a market for Fruitflow® will be affected by many factors, some of which are beyond Provexis' control, including the emergence of newer, more successful food IP and products and the cost of Fruitflow®. Notwithstanding the health claims made in respect of Fruitflow®, there can be no guarantee that Provexis' targeted customer base for the product will purchase or continue to purchase the product. If a market fails to develop or develops more slowly than anticipated, Provexis may be unable to recover the losses it may have incurred in the development of Fruitflow® and may never achieve profitability.

Limited product offering

Provexis has only have one product, Fruitflow®, and any problems with the commercial success of Fruitflow® will impact the financial performance of Provexis.

Intellectual property protection

Provexis is heavily dependent on its intellectual property and, in particular, its patents. No assurance can be given that any pending patent applications or any future patent applications will result in granted patents, that any patents will be granted on a timely basis, that the scope of any copyright or patent protection will exclude competitors or provide competitive advantages to Provexis, that any of Provexis' patents will be held valid if challenged, or that third parties will not claim rights in or ownership of the copyright, patents and other proprietary rights held by Provexis.

Further, there can be no assurance that others have not developed or will not develop similar products, duplicate any of Provexis' products or design around any patents held by Provexis. Others may hold or receive patents which contain claims having a scope that covers products developed by Provexis (whether or not patents are issued to Provexis).

Provexis may rely on patents to protect its assets. These rights act only to prevent a competitor copying and not to prevent a competitor from independently developing products that perform the same functions. No assurance can be given that others will not independently develop or otherwise acquire substantially equivalent functional food IP or otherwise gain access to Provexis' unpatented proprietary technology or disclose such technology or that Provexis can ultimately protect meaningful rights to such unpatented technology.

Once granted, a patent can be challenged both in the patent office and in the courts by third parties. Third parties can bring material and arguments which the patent office granting the patent may not have seen. Therefore, issued patents may be found by a court of law or by the patent office to be invalid or unenforceable or in need of further restriction.

A substantial cost may be incurred if Provexis is required to assert its intellectual property rights, including any patents or trade marks against third parties. Litigation is costly and time consuming and there can be no assurance that Provexis will have, or will be able to devote, sufficient resources to pursue such litigation. Potentially unfavourable outcomes in such proceedings could limit Provexis' intellectual property rights and activities. There is no assurance that obligations to maintain Provexis' know how would not be breached or otherwise become known in a manner which provides Provexis with no recourse.

Any claims made against Provexis' intellectual property rights, even without merit, could be time consuming and expensive to defend and could have a materially detrimental effect on Provexis' resources. A third party asserting infringement claims against Provexis could require Provexis to cease the infringing activity and/or require Provexis to enter into licensing and royalty arrangements. The third party could also take legal action which could be costly. In addition, Provexis may be required to develop alternative non-infringing solutions that may require significant time and substantial unanticipated resources. There can be no assurance that such claims will not have a material adverse effect on Provexis' business, financial condition or results.

Ian Ford

Finance Director

Consolidated statement of comprehensive income

		Year	Year
		ended	ended
		31 March	31 March
		2015	2014

	Notes	£	£


Revenue	1,3	38,224	3,967
Research and development costs	4	(180,497)	(142,985)
Administrative costs		(355,964)	(879,958)

Underlying operating loss		(408,862)	(577,961)
Costs of demerger of SiS (Science in Sport) Limited	10	-	(49,824)
Share based payment charges	17	(89,375)	(391,191)

Loss from continuing operations	4	(498,237)	(1,018,976)

Finance income	7	5,077	4,889
Loss before taxation		(493,160)	(1,014,087)

Taxation	8	5,407	15,823

Loss for the year from continuing operations		(487,753)	(998,264)

Discontinued operation
Profit for the year from discontinued operation		-	1,434,983

(Loss) / profit and total comprehensive (expense) / income for the year		(487,753)	436,719

Attributable to:
Owners of the parent	18	(435,598)	488,353
Non-controlling interest	18	(52,155)	(51,634)
(Loss) / profit and total comprehensive (expense) / income for the year	18	(487,753)	436,719

(Loss) / earnings per share to owners of the parent
From continuing and discontinued operations
Basic - pence	9	(0.03)	0.03
Diluted - pence	9	(0.03)	0.03

From continuing operations
Basic - pence	9	(0.03)	(0.06)
Diluted - pence	9	(0.03)	(0.06)

Consolidated statement of financial position

Company number 05102907		As at	As at
		31 March	31 March
		2015	2014
	Notes	£	£

Assets
Current assets
Trade and other receivables	13	53,348	112,637
Corporation tax asset	8	21,230	15,823
Cash and cash equivalents		285,403	514,827
Total current assets		359,981	643,287

Total assets		359,981	643,287

Liabilities
Current liabilities
Trade and other payables	14	(114,081)	(108,212)
Total current liabilities		(114,081)	(108,212)
Net current assets		245,900	535,075

Total liabilities		(114,081)	(108,212)

Total net assets		245,900	535,075

Capital and reserves attributable to owners of the parent company
Share capital	16	1,584,846	1,554,816
Share premium reserve	18	16,298,043	16,183,870
Warrant reserve	18	26,200	26,200
Merger reserve	18	6,599,174	6,599,174
Retained earnings	18	(23,886,736)	(23,505,513)
		621,527	858,547
Non-controlling interest	18	(375,627)	(323,472)
Total equity		245,900	535,075

Consolidated statement of cash flows

		Year	Year
		ended	ended
		31 March	31 March
		2015	2014

	Notes	£	£

Cash flows from operating activities
Loss after tax		(487,753)	(998,264)
Adjustments for:
Depreciation	12	-	9,140
Net finance income		(5,077)	(4,889)
Taxation		(5,407)	(15,823)
Share-based payment charge		89,375	391,191
Changes in trade and other receivables		(1,783)	63,177
Changes in trade and other payables		5,869	(225,460)
Net cash flow from continuing operations		(404,776)	(780,928)

Tax credits received		-	220,717
Cash flow from discontinued operations		-	(13,133)
Total cash flow from operations		(404,776)	(573,344)

Cash flow from investing activities
Interest received		4,949	4,763
Net cash flow from continuing operations		4,949	4,763
Cash flow from discontinued operations		-	(113,599)
Total cash flow from investing activities		4,949	(108,836)

Cash flow from financing activities
Proceeds from issue of share capital		170,403	286,750
Proceeds from exercise of share options		-	15,750
Net cash flow from continuing operations		170,403	302,500
Cash flow from discontinued operations			(23,797)
Total cash flow from financing activities		170,403	278,703

Net decrease in cash and cash equivalents
- from continuing operations		(229,424)	(252,948)
- from discontinued operations		-	(150,529)
- add: inter company debt repaid by SiS business at demerger		-	290,000
- add: bank overdraft held by SiS business at demerger		-	11,692
Net decrease in cash and cash equivalents		(229,424)	(101,785)

Opening cash and cash equivalents		514,827	616,612
Closing cash and cash equivalents		285,403	514,827

Consolidated statement of changes in equity


	Share capital	Share premium	Warrant reserve	Merger reserve	Retained earnings	Total equity attributable to owners of the parent	Non-controlling interests	Total equity
	£	£	£	£	£	£	£	£

At 31 March 2013	5,134,170	20,769,423	60,000	6,599,174	(24,385,057)	8,177,710	(271,838)	7,905,872

Share-based charges	-	-	-	-	391,191	391,191	-	391,191

Demerger of SiS (Science in Sport) - issue redeemable shares	50,000	-	-	-	-	50,000	-	50,000

Demerger of SiS (Science in Sport) - issue SiS cancellation shares	1,518,651	(1,518,651)	-	-	-	-	-	-

Demerger of SiS (Science in Sport) - redeem redeemable shares	(50,000)	-	-	-	-	(50,000)	-	(50,000)

Demerger of SiS (Science in Sport) - transfer to Science in Sport plc	(5,134,170)	(3,370,275)	-	-	-	(8,504,445)	-	(8,504,445)

Warrants cancelled during the year - equity financing facility	-	2,038	(60,000)	-	-	(57,962)	-	(57,962)

Warrants issued during the year - equity financing facility	-	-	26,200	-	-	26,200	-	26,200

Issue of shares - equity financing facility 11 September 2013	31,000	255,750	-	-	-	286,750	-	286,750

Issue of shares - equity financing facility fee 11 September 2013	3,415	31,585	-	-	-	35,000	-	35,000

Issue of shares - share options exercised 22 November 2013	1,750	14,000	-	-	-	15,750	-	15,750

Total comprehensive income for the year	-	-	-	-	488,353	488,353	(51,634)	436,719


At 31 March 2014	1,554,816	16,183,870	26,200	6,599,174	(23,505,513)	858,547	(323,472)	535,075

Share-based charges	-	-	-	-	89,375	89,375	-	89,375

Equity financing facility fee - charge for year	-	-	-	-	(35,000)	(35,000)	-	(35,000)

Issue of shares - equity financing facility 29 April 2014	7,000	38,403	-	-	-	45,403	-	45,403

Issue of shares - equity financing facility 15 December 2014	23,030	101,970	-	-	-	125,000	-	125,000

Equity financing facility - warrants charged to share premium account	-	(26,200)	-	-	-	(26,200)	-	(26,200)

Total comprehensive expense for the year	-	-	-	-	(435,598)	(435,598)	(52,155)	(487,753)


At 31 March 2015	1,584,846	16,298,043	26,200	6,599,174	(23,886,736)	621,527	(375,627)	245,900

Notes to the preliminary results for the year ended 31 March 2015

1. Accounting policies

General information

Provexis plc is a public limited company incorporated and domiciled in the United Kingdom (registration number 05102907). The address of the registered office is Prospect House, Queens Road, Reading, Berkshire RG1 4RP, UK.

The main activities of the Group are those of developing and licensing the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient for the global functional food sector.

Company reorganisation and demerger

SiS (Science in Sport) Limited was demerged from Provexis plc with effect from 9 August 2013 by way of a capital reduction demerger and transferred to a newly incorporated parent company, Science in Sport plc.

Pursuant to the terms of the demerger agreement Science in Sport plc allotted and issued to the holders of ordinary shares in the capital of Provexis plc 15,188,000 ordinary shares of 10 pence each in consideration of the transfer to Science in Sport plc by Provexis plc of the whole of the issued share capital of SiS (Science in Sport) Limited. Science in Sport plc was admitted to the AIM segment of the London Stock Exchange's market for listed securities as from 9 August 2013.

At the date of the demerger, Science in Sport plc acquired the entire issued share capital of SiS (Science in Sport) Limited in return for issuing shares to the shareholders of Provexis plc.

These transactions resulted in the demerger of SiS (Science in Sport) Limited from the Group.

SiS (Science in Sport) Limited represented a separate major line of business for the Group under the definitions within IFRS 5, hence the results of SiS (Science in Sport) Limited up to the date of the demerger are shown as discontinued in these financial statements in the prior year comparatives for the year ended 31 March 2014.

Prior to the demerger, Provexis plc converted £448,163 of an intercompany debt from SiS (Science in Sport) Limited into equity by way of a capital contribution. At the time of the demerger, a payment of £290,000 was made to Provexis plc to settle the remaining outstanding intercompany debt.

Basis of preparation

The financial information set out in this release does not constitute the Company's full statutory accounts for the year ended 31 March 2015 for the purposes of section 434(3) of the Companies Act 2006, but it is derived from those accounts that have been audited. Statutory accounts for 2014 have been delivered to the Registrar of Companies and those for 2015 will be delivered after the forthcoming AGM. The auditors have reported on those accounts; their report was unqualified, and did not contain statements under s498(2) or (3) Companies Act 2006 in either 2015 or 2014.

While the financial information included in this preliminary announcement has been prepared in accordance with the recognition and measurement principles of International Financial Reporting Standards (IFRS) as endorsed for the use in the European Union, this announcement does not itself contain sufficient information to comply with IFRS. The Company expects to publish full financial statements for the year ended 31 March 2015 that comply with IFRS in September 2015.

The accounting policies set out below have been applied to all periods presented in these Group financial statements and are in accordance with IFRS, as adopted by the European Union, and International Financial Reporting Interpretations Committee ('IFRIC') interpretations that were applicable for the year ended 31 March 2015.

These accounting policies are consistent with those applied in the year ended 31 March 2014, as amended to reflect any new Standards, Amendments to Standards and interpretations which are mandatory for the year ended 31 March 2015, these are detailed below:

IAS 27 (revised): Separate financial statements (effective 1 January 2014);

IAS 28 (revised): Associates and joint ventures (effective 1 January 2014);

IFRS 10: Consolidated financial statements (effective 1 January 2014);

IFRS 11: Joint arrangements (effective 1 January 2014);

IFRS 12: Disclosure of interests in other entities (effective 1 January 2014);

Amendments to IAS 32 (Dec 2011) Offsetting financial assets and financial liabilities (effective 1 January 2014); and

Amendments to IAS 36 Recoverable amounts disclosures for non-financial assets (effective 1 January 2014).

The adoption of these Standards and Interpretations has not had a material impact on the consolidated financial statements of the Group.

The following standards, interpretations and amendments have been issued but are not yet effective and will be adopted at the point they are effective:

IFRS 9: Financial instruments: Classification and measurement;

Annual improvements to IFRSs 2011-2013 cycle (effective period commencing after 1 July 2014);

IFRS 14 Regulatory deferral accounts;

IFRS 15 Revenue from contracts with customers (effective period commencing after 1 February 2015);

Defined benefit plans: employee contributions (Amendments to IAS 19);

Clarification of acceptable methods of depreciation and amortisation - amendments to IAS 16 and IAS 38;

Sale or contribution of assets between an investor and its associate or joint venture;

Amendments to IFRS 11: Accounting for acquisitions of interest in joint operations; and

Amendments to IAS 27: Equity method in separate financial statements.

The Directors do not expect that the adoption of these Standards and Interpretations in future periods will have a material impact on the consolidated financial statements of the Group. There are a number of standards, interpretations and amendments to published accounts not listed above which the directors consider not to be relevant to the Group.

Going concern

The Group's business activities together with the factors likely to affect its future development are set out in the strategic report. The financial position of the Group, its cash flows and liquidity position are also set out in the strategic report. In addition note 2 to the financial statements includes the Group's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments and its exposure to credit and liquidity risk.

On 4 June 2015 the Group also announced that it had joined PrimaryBid.com (www.primarybid.com), an online platform dedicated to equity crowdfunding for AIM-listed companies which is further detailed in note 16. On 3 July 2015 the Group announced that it had raised net proceeds of £267,400 via the placing of 62,222,223 new ordinary shares of 0.1p each at a gross 0.45p per share ('the placing shares') with investors using the Primarybid.com platform. The placing shares were admitted to AIM on 9 July 2015.

Accordingly the going concern basis has been used in preparing the financial statements.

Basis of consolidation

Subsidiaries are all entities (including special purpose entities) over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

The consolidated financial information presents the results of the Company and its subsidiaries, Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited as if they formed a single entity ('the Group'). All subsidiaries share the same reporting date, 31 March, as Provexis plc. All intra group balances are eliminated in preparing the financial statements.

The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group. The cost of an acquisition is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any non-controlling interest. The excess of the cost of acquisition over the fair value of the Group's share of the identifiable net assets acquired is recorded as goodwill. The direct costs of acquisition are recognised immediately as an expense.

Non-controlling interest

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Revenue

Revenue comprises the fair value received or receivable for exclusivity arrangements, collaboration agreements, royalties and sales net of sales rebates and excluding VAT and trade discounts.

The accounting policies for the principal revenue streams of the Group are as follows:

(i) Exclusivity arrangements and collaboration agreements are recognised as revenue in the accounting period in which the related services, or required activities, are performed or specified conditions are fulfilled in accordance with the terms of completion of the specific transaction.

(ii) Royalty income relating to the sale by a licensee of licensed product is recognised on an accruals basis in accordance with the substance of the relevant agreement and based on the receipt from the licensee of the relevant information to enable calculation of the royalty due.

Segment reporting

The Group determines and presents operating segments based on the information that internally is provided to the Chairman, who is the Group's 'chief operating decision maker' ('CODM').

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group's other components. An operating segment's operating results are reviewed regularly by the CODM to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

Segment results that are reported to the Group Board include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

Segment capital expenditure is the total cost incurred during the period to acquire property, plant and equipment, and intangible assets.

Use of non-GAAP profit measure - underlying operating profit

The directors believe that the operating loss before amortisation and impairment of acquired intangibles, share based payments and exceptional items measure provides additional useful information for shareholders on underlying trends and performance. This measure is used for internal performance analysis. Underlying operating loss is not defined by IFRS and therefore may not be directly comparable with other companies' adjusted profit measures. It is not intended to be a substitute for, or superior to IFRS measurements of profit.

Exceptional items are those material items which, by virtue of their size or incidence, are presented separately in the Statement of Comprehensive Income to give a full understanding of the Group's underlying financial performance. Transactions which may give rise to exceptional items include the restructuring of business activities and acquisitions. A reconciliation of underlying operating profit to statutory operating profit is set out on the face of the Statement of Comprehensive Income.

Leased assets

Leases, which contain terms whereby the Group does not assume substantially all the risks and rewards incidental to ownership of the leased item are classified as operating leases. Operating lease rentals are charged to the statement of comprehensive income on a straight line basis over the lease term.

Intangible assets

Research and development

Certain Group products are in the research phase and others are in the development phase. Expenditure incurred on the development of internally generated products is capitalised if it can be demonstrated that:

● It is technically feasible to develop the product for it to be sold;

● Adequate resources are available to complete the development;

● There is an intention to complete and sell the product;

● The Group is able to sell the product;

● Sale of the product will generate future economic benefits; and

● Expenditure on the project can be measured reliably.

The value of the capitalised development cost is assessed for impairment annually. The value is written down immediately if impairment has occurred. Development costs are not being amortised as income has not yet been realised from the underlying technology. Development expenditure, not satisfying the above criteria, and expenditure on the research phase of internal projects is recognised in the statement of comprehensive income as incurred.

Patents and trade marks

The costs incurred in establishing patents and trade marks are either expensed or capitalised in accordance with the corresponding treatment of the development expenditure for the product to which they relate.

Non-current assets held for sale or distribution and disposal groups

Non-current assets and disposal groups are classified as held for sale when, at the year end:

- they are available for immediate sale;

- management is committed to a plan to sell;

- it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn;

- an active programme to locate a buyer has been initiated;

- the asset or disposal group is being marketed at a reasonable price in relation to its fair value; and

- a sale is expected to complete within 12 months from the date of classification.

Non-current assets and disposal groups classified as held for sale are measured at the lower of:

- their carrying amount immediately prior to being classified as held for sale in accordance with the Group's accounting policy; and

- fair value less costs to sell.

Following their classification as held for sale, non-current assets (including those in a disposal group) are not depreciated.

The results of operations disposed during the year are included in the consolidated statement of comprehensive income up to the date of disposal.

A discontinued operation is a component of the Group's business that represents a separate major line of business or geographical area of operations or is a subsidiary acquired exclusively with a view to resale, that has been disposed of, has been abandoned or that meets the criteria to be classified as held for sale.

Discontinued operations are presented in the consolidated statement of comprehensive income as a single line which comprises the post-tax profit or loss of the discontinued operation along with the post-tax gain or loss recognised on the re-measurement to fair value less costs to sell or on disposal of the assets or disposal groups constituting discontinued operations. The cash flows from discontinued operations are also disclosed as a single-line item in each category of the cash flow statement.

Impairment of assets

Assets that have a finite useful life but that are not yet in use and are therefore not subject to amortisation or depreciation are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment annually and when events or circumstances suggest that the carrying amount may not be recoverable, an impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in the statement of comprehensive income, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior periods. A reversal of an impairment loss is recognised immediately in the statement of comprehensive income, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. Impairment losses on goodwill are not reversed.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is calculated as follows:

Raw materials - cost of purchase on first in, first out basis.

Work in progress and finished goods - cost of raw materials and labour, together with attributable overheads based on the normal level of activity.

Net realisable value is based on estimated selling price less further costs to completion and disposal. A charge is made to the income statement for slow moving inventories. The charge is reviewed at each balance sheet date.

Financial instruments

Financial assets

The Group's financial assets are comprised of 'trade and other receivables' and 'cash and cash equivalents'. They are recognised initially at their fair value and subsequently at amortised cost. The Group will assess at each reporting date whether there is objective evidence that the financial asset is impaired. If an asset is judged to be impaired the carrying amount of the asset will be adjusted to its impaired valuation.

Financial liabilities

The Group's financial liabilities comprise 'trade and other payables' and 'borrowings'. These are recognised initially at fair value and subsequently at amortised cost.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand.

Government grants

Government grants are recognised when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions. Government grants are recognised in the statement of comprehensive income in the same period to which the costs that they are intended to compensate are expensed.

Taxation

Current tax is provided at amounts expected to be recovered or to be paid using the tax rates and tax laws that have been enacted or substantively enacted at the reporting date. When research and development tax credits are claimed they are recognised on an accruals basis and are included as a taxation credit.

Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability on the balance sheet differs from its tax base, except for differences arising on:

· The initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting or taxable profit; and

· Investments in subsidiaries where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future.

Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profits will be available against which the difference can be utilised.

The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the deferred tax liabilities/(assets) are settled/(recovered). Deferred tax balances are not discounted.

Deferred tax assets and liabilities are offset when the Group has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority on either:

· The same taxable Group Company; or

· Different Group entities which intend to settle current tax assets and liabilities on a net basis, or to realise the assets and settle the liabilities simultaneously, on each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

Foreign currency translation

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the statement of comprehensive income.

Benefits for Directors and consultants

(i) Share-based payment transactions

The Group operates an equity-settled, share-based compensation plan. Vesting conditions are service conditions and performance conditions only. Where share options are awarded to employees and others providing similar services, the fair value of the options at the date of grant is charged to the statement of comprehensive income over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each reporting date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options when granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied. The cumulative charge is not adjusted for failure to achieve a market vesting condition. If market related terms and conditions of options are modified before they vest, the change in the fair value of the options, measured immediately before and after the modification, is also charged to the statement of comprehensive income over the remaining vesting period. If non-market related terms and conditions of options are modified before they vest, the number of instruments expected to vest at each reporting date, and therefore the cumulative charge, is amended accordingly. Where equity instruments are granted to persons other than employees and others providing similar services, the statement of comprehensive income is charged with the fair value of goods and services received.

The proceeds received when options are exercised, net of any directly attributable transaction costs, are credited to share capital (nominal value) and the remaining balance to share premium.

National insurance on share options

All employee option holders sign statements that they will be liable for any employers national insurance arising on the exercise of share options.

Interest income

Interest income is recognised on a time-proportion basis using the effective interest rate method.

Warrants

The Group has issued warrants to Darwin Strategic Limited, initially as part of the Equity Financing Facility and with effect from June 2015 as part of PrimaryBid.com. These warrants have been measured at fair value at the date of grant using an appropriate options pricing model.

The fair value of the warrants had been held on the statement of financial position within prepayments and in the warrants reserve within equity. The prepayment was released in full against share premium in the year ended 31 March 2015. The warrants reserve will be released to share premium if the warrants are exercised. If the warrants lapse then the reserve will be transferred to retained earnings.

Critical accounting estimates and judgements

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Estimates and judgements are continually made and are based on historic experience and other factors, including expectations of future events that are believed to be reasonable in the circumstances.

As the use of estimates is inherent in financial reporting, actual results could differ from these estimates. The directors believe the following to be the key areas of estimation and judgement:

(i) Research and development

Under IAS 38 Intangible Assets, development expenditure which meets the recognition criteria of the standard must be capitalised and amortised over the useful economic lives of intangible assets from product launch.

(ii) Share-based payments

The Group operates an equity-settled, share-based compensation plan. The charge for share-based payments is determined based on the fair value of awards at the date of grant partly by use of the Black-Scholes pricing model which require judgements to be made regarding expected volatility, dividend yield, risk free rates of return and expected option lives. The inputs used in these pricing models to calculate the fair values are set out in note 17. An element of the share-based payment charge also relies on certain assumptions over the future performance of the share price which may not be met or may be exceeded by the time the relevant awards vest.

(iii) Valuation of inventories

Inventories are valued at the lower of cost and net realisable value. Cost comprises direct materials, labour and, where appropriate, overheads that have been incurred in bringing the inventory to its present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

2. Financial risk management

2.1 Financial risk factors

The Group's activities inevitably expose it to a variety of financial risks: market risk (including currency risk, cash flow interest rate risk and fair value interest rate risk), credit risk and liquidity risk.

It is Group policy not to enter into speculative positions using complex financial instruments. The Group's primary treasury objective is to minimise exposure to potential capital losses whilst at the same time securing favourable market rates of interest on Group cash deposits using money market deposits with banks. Cash balances used to settle the liabilities from operating activities are also maintained in current accounts which earn interest at variable rates.

(a) Market risk

Foreign exchange risk

The Group's largest contract, the long-term Alliance Agreement with DSM Nutritional Products for Fruitflow®, is primarily denominated in Euros. The Alliance Agreement is underpinned by a financial model which is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales.

DSM Nutritional Products seeks to sell Fruitflow® in Euros, but its customers for Fruitflow® are world-wide and world-wide exchange rate fluctuations may have an impact on the revenues accruing to DSM, and thus the profit share accruing to the Group. The cost of goods for Fruitflow® is primarily denominated in and incurred in Euros.

The Group incurred minimal expenditure in foreign currencies during the year, and the prior year, and it is not considered that the Group has a material exposure to foreign currency rate risk.

Cash flow and fair value interest rate risk

The Group's interest rate risk arises from medium term and short term money market deposits. Deposits which earn variable rates of interest expose the Group to cash flow interest rate risk. Deposits at fixed rates expose the Group to fair value interest rate risk.

The Group analyses its interest rate exposure on a dynamic basis throughout the year.

(b) Credit risk

Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure in relation to outstanding receivables. Group policy is to place deposits with institutions with investment grade A2 or better (Moody's credit rating) and deposits are made in sterling only. The Group does not expect any losses from non-performance by these institutions. Management believes that the carrying value of outstanding receivables and deposits with banks represents the Group's maximum exposure to credit risk.

Liquidity risk arises from the Group's management of working capital, it is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due. Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents and management monitors rolling forecasts of the Group's liquidity on the basis of expected cash flow.

The Group had trade and other payables at the statement of financial position date of £114,081 (2014: £108,212) as disclosed in note 14.

2.2 Capital risk management

The Group considers its capital to comprise its ordinary share capital, share premium, warrant reserve, merger reserve and accumulated retained earnings as disclosed in the consolidated statement of financial position.

The Group remains funded primarily by equity capital. The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for equity holders of the Company and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

3. Segmental reporting

Following the demerger of SiS (Science in Sport) Limited in August 2013 the directors have determined that only one operating segment exists under the terms of International Financial Reporting Standard 8 'Operating Segments', as the Group is organised and operates as a single business unit and all activities are based in the UK. The Group's reporting segment is determined based on the Group's internal reporting to the Chief Operating Decision Maker (CODM). The CODM has been determined to be the Chairman of the Board of Directors as he is primarily responsible for the allocation of resources to segments and the assessment of performance of the segments.

The CODM uses underlying operating profit/(loss) as the key measure of the segments' results as it reflects the segments' underlying trading performance for the financial period under evaluation.

Underlying operating profit/(loss) is a consistent measure within the Group which measures the performance of the segment before goodwill and acquired intangible asset amortisation and impairment, share based payment charges, restructuring charges and acquisition costs arising from acquisitions.

4. Loss from continuing operations

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£
Loss from continuing operations is stated after charging:

Depreciation of plant and equipment	-	9,140
Research and development costs	180,497	142,985
Foreign exchange losses / (gains)	2,553	(603)
Costs of demerger of SiS (Science in Sport) Limited	-	49,824
Operating lease costs - land and buildings	-	12,266
Equity-settled share based payment expense	89,375	391,191
Defined contribution pension expense	-	7,624

The total fees of the Group's auditor, for services provided are analysed below:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£
Audit services
Parent company	13,000	13,000
Subsidiaries	12,000	12,000
Tax services - compliance
Parent company	2,000	2,000
Subsidiaries	3,000	3,000
Other services
iXBRL services	2,000	2,000
Corporate finance - demerger of SiS (Science in Sport)	-	15,000

Total fees	32,000	47,000

The Group engaged Chantrey Vellacott DFK LLP to assist the Group with the demerger of SiS (Science in Sport) Limited from the Provexis Group to a new company called Science in Sport plc. Science in Sport plc engaged Chantrey Vellacott DFK LLP to assist it with the admission of its entire issued and to be issued ordinary share capital to trading on AIM on 9 August 2013.

5. Wages and salaries

The average monthly number of persons (including all directors) employed by the Group during the year for continuing operations was as follows:

	Year ended 31 March 2015	Year ended 31 March 2014

Research and development consultants	1	-
Directors	3	4
	4	4

Their aggregate emoluments were:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Wages and salaries	169,253	289,307
Social security costs	-	23,960
Other pension and insurance benefits costs	-	11,476
Total cash settled emoluments	169,253	324,743
Accrued holiday pay	-	(28,343)
Share-based payment remuneration charge: equity settled	54,375	391,191
Total emoluments	223,628	687,591

6. Directors' remuneration

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£
Directors
Aggregate emoluments	149,253	245,600
Company pension contributions	-	6,046
	149,253	251,646
Share based payment remuneration charge: equity settled	46,397	417,789
Total Directors' emoluments	195,650	669,435

Emoluments disclosed above include the following amounts in respect of the highest paid director:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Aggregate emoluments	76,251	89,814
Company pension contributions	-	3,678
Share based payment remuneration charge: equity settled	23,198	259,707
Total of the highest paid director's emoluments	99,449	353,199

During the year the directors did not participate in defined contribution pension schemes (2014: two directors participated in defined contribution pension schemes).

Directors' emoluments in the year ended 31 March 2014 (2015: £NIL) include amounts attributable to benefits in kind comprising private medical insurance on which the directors were assessed for tax purposes. The amounts attributable to benefits in kind are stated at cost to the Group, which is also the tax value of the attributable benefits.

7. Finance income

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Finance income
Bank interest receivable	5,077	4,889
	5,077	4,889

8. Taxation

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£
Current tax income
United Kingdom corporation tax - research and development credit	5,407	15,823
Taxation credit	5,407	15,823

The tax assessed for the year is different from the standard rate of corporation tax in the UK. The differences are explained below:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Loss before tax	493,160	1,014,087

Loss before tax multiplied by the standard rate of corporation tax in the UK of 21% (2014: 23%)	103,564	233,240
Effects of:
Expenses not deductible for tax purposes	(19,539)	(535)
Difference between depreciation and capital allowances	362	(2,102)
Other short-term timing differences	-	(89,974)
Unutilised tax losses and other deductions arising in the year	(69,487)	(130,271)
Additional deduction for R&D expenditure	4,351	18,380
Surrender of tax losses for R&D tax credit refund	(2,425)	(17,262)
Share scheme deduction	(11,419)	4,347
Adjustments in respect of prior years	-	-
Total tax credit for the year	5,407	15,823

At 31 March 2015 the Group UK tax losses to be carried forward are estimated to be £18,100,000 (2014: £17,833,920).

Income tax asset receivable within one year	31 March 2015	31 March 2014
	£	£

Corporation tax recoverable	21,230	15,823
	21,230	15,823

9. Earnings per share and diluted earnings per share

Basic earnings per share amounts are calculated by dividing the profit attributable to owners of the parent by the weighted average number of ordinary shares in issue during the financial year.

Diluted earnings per share amounts are calculated by dividing the profit attributable to owners of the parent by the weighted average number of ordinary shares in issue during the financial year adjusted for the effects of potentially dilutive options. The dilutive effect is calculated on the full exercise of all potentially dilutive ordinary share options granted by the Group.

	Year ended 31 March 2015			Year ended 31 March 2014
	Basic	Potentially dilutive share options and warrants	Diluted	Basic	Potentially dilutive share options and warrants	Diluted

(Loss) / profit - £
Continuing operations	(435,598)	-	(435,598)	(946,630)	-	(946,630)
Discontinued operations	-	-	-	1,434,983	-	1,434,983
Total operations attributable to owners	(435,598)	-	(435,598)	488,353	-	488,353

Share options	-	-	-	-	11,299,562	-
Weighted average number of shares	1,567,947,710	-	1,567,947,710	1,537,655,373	11,299,562	1,548,954,935

(Loss) / earnings per share (pence)
Continuing operations	(0.03)	-	(0.03)	(0.06)	-	(0.06)
Discontinued operations	-	-	-	0.09	-	0.09
Total	(0.03)	-	(0.03)	0.03	-	0.03

There have been no transactions involving ordinary shares between the reporting date and the date of approval of these financial statements which would significantly change the earnings per share calculations shown above.

The earnings per share for continuing operations do not include potentially dilutive share options and warrants on the basis that the continuing operations made a loss.

10. Discontinued operations

SiS (Science in Sport) Limited , which was acquired by Provexis plc in June 2011, was demerged from Provexis with effect from 9 August 2013 by way of a capital reduction demerger and transferred to a newly incorporated parent company, Science in Sport plc.

The Company incurred certain demerger costs as part of this process:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Costs of demerger of SiS (Science in Sport) Limited	-	49,824

Pursuant to the terms of the demerger agreement Science in Sport plc allotted and issued to the holders of ordinary shares in the capital of Provexis plc 15,188,000 ordinary shares of 10 pence each in consideration of the transfer to Science in Sport plc by Provexis plc of the whole of the issued share capital of SiS (Science in Sport) Limited. Science in Sport plc was admitted to the AIM segment of the London Stock Exchangeʼs market for listed securities as from 9 August 2013.

At the date of the demerger, Science in Sport plc acquired the entire issued share capital of SiS (Science in Sport) Limited in return for issuing shares to the shareholders of Provexis plc.

These transactions resulted in the demerger of SiS (Science in Sport) Limited from the Group.

SiS (Science in Sport) Limited represented a separate major line of business for the Group under the definitions within IFRS 5, hence the results of SiS (Science in Sport) Limited up to the date of the demerger are shown as discontinued in these financial statements, in the year ended 31 March 2014.

Further details of the demerger are provided in the Group's annual report and accounts for the year ended 31 March 2014.

11. Intangible assets

	Goodwill	Development costs	Trade marks	Patents / recipes / formulations	Covenants not to compete	Customer relationships	Website development costs	Total
	£	£	£	£	£	£	£	£


Cost
At 1 April 2014	7,265,277	158,166	-	-	-	-	-	7,423,443
At 31 March 2015	7,265,277	158,166	-	-	-	-	-	7,423,443

Amortisation and Impairment
At 1 April 2014	7,265,277	158,166	-	-	-	-	-	7,423,443
At 31 March 2015	7,265,277	158,166	-	-	-	-	-	7,423,443

Net book value
At 31 March 2015	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	-	-	-	-	-




Cost
At 1 April 2013	11,703,268	158,166	1,004,029	180,886	22,480	1,228,696	174,999	14,472,524
Additions	-	-	-	-	-	-	7,172	7,172
Demerger of SiS (Science in Sport)	(4,437,991)	-	(1,004,029)	(180,886)	(22,480)	(1,228,696)	(182,171)	(7,056,253)
At 31 March 2014	7,265,277	158,166	-	-	-	-	-	7,423,443

Amortisation and impairment
At 1 April 2013	7,265,277	158,166	186,714	47,691	13,238	228,495	19,441	7,919,022
Charge for year	-	-	35,229	8,999	2,498	43,112	11,738	101,576
Demerger of SiS (Science in Sport)	-	-	(221,943)	(56,690)	(15,736)	(271,607)	(31,179)	(597,155)
At 31 March 2014	7,265,277	158,166	-	-	-	-	-	7,423,443

Net book value
At 31 March 2014	-	-	-	-	-	-	-	-
At 31 March 2013	4,437,991	-	817,315	133,195	9,242	1,000,201	155,558	6,553,502

Development costs represent costs incurred in registering patents that meet the capitalisation criteria set out in IAS 38, see also note 1.

12. Plant and equipment

	Fixtures, fittings, plant and equipment	Laboratory equipment	Total
	£	£	£
Cost
At 1 April 2014	74,096	147,145	221,241
Disposals	(74,096)	(78,420)	(152,516)
At 31 March 2015	-	68,725	68,725

Depreciation
At 1 April 2014	74,096	147,145	221,241
Disposals	(74,096)	(78,420)	(152,516)
At 31 March 2015	-	68,725	68,725

Net book value
At 31 March 2015	-	-	-
At 31 March 2014	-	-	-

	Leasehold improvements	Fixtures, fittings, plant and equipment	Laboratory equipment	Motor vehicles	Total
	£	£	£	£	£
Cost
At 1 April 2013	230,956	659,045	147,145	11,527	1,048,673
Additions	-	106,453	-	-	106,453
Demerger of SiS (Science in Sport)	(230,956)	(691,402)	-	(11,527)	(933,885)
At 31 March 2014	-	74,096	147,145	-	221,241

Depreciation
At 1 April 2013	58,706	198,528	147,145	9,374	413,753
Charge for the year	16,409	54,702	-	1,722	72,833
Demerger of SiS (Science in Sport)	(75,115)	(179,134)	-	(11,096)	(265,345)
At 31 March 2014	-	74,096	147,145	-	221,241

Net book value
At 31 March 2014	-	-	-	-	-
At 31 March 2013	172,250	460,517	-	2,153	634,920

13. Trade and other receivables

	31 March 2015	31 March 2014
	£	£

Amounts receivable within one year:
Trade receivables	240	-
Less: provision for impairment of trade receivables	-	-
Trade receivables - net	240	-
Other receivables	18,750	33,207
Total financial assets other than cash and cash equivalents classified as loans and receivables	18,990	33,207
Prepayments and accrued income	34,358	79,430
Total trade and other receivables	53,348	112,637

Trade receivables represent debts due for the sale and rental of goods to customers. The provision for impairment of receivables is estimated by the Group's management based on prior experience.

The balance at 31 March 2015 of £53,348 is £59,289 less than the prior year due predominantly to a decrease in prepayments relating to the group's Darwin Strategic Limited Equity Financing Facility.

Trade receivables are denominated in Sterling. The directors consider that the carrying amount of these receivables approximates to their fair value. Trade and other receivables are categorised as loans and receivables under IAS 39.

All amounts shown under receivables fall due for payment within one year.

The Group does not hold any collateral as security.

As at 31 March 2015 there were no trade receivables (2014: £Nil) that were past due but not impaired, and consequently there was no provision for impairment (2014: £Nil).

Movements on the group provision for impairment of trade receivables are as follows:

	31 March 2015	31 March 2014
	£	£

At beginning of the year	-	32,233
Provided during the year	-	2,000
Demerger of SiS (Science in Sport) Limited	-	(34,233)
	-	-

The movement on the provision for impaired receivables in the prior year is included in administrative expenses within discontinued operations in the consolidated statement of comprehensive income.

Other classes of financial assets included within trade and other receivables do not contain impaired assets.

14. Trade and other payables

	31 March 2015	31 March 2014
	£	£

Trade payables	38,135	19,028
Accruals	72,075	85,313
Total financial liabilities measured at amortised cost	110,210	104,341
Other taxes and social security	3,871	3,871
Total trade and other payables	114,081	108,212

The directors consider that the carrying amount of these liabilities approximates to their fair value.

All amounts shown fall due within one year.

15. Deferred tax

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 21% (2014: 21%).

No amounts in respect of deferred tax were recognised in the income statement from continuing operations or charged / credited to equity for the current or prior year.

Deferred tax assets amounting to £3,810,272 (2014: £3,789,701) have not been recognised on the basis that their future economic benefit is not certain. Assuming a prevailing tax rate of 21% (2014: 21%) when the timing differences reverse, the unrecognised deferred tax asset comprises:

	Year ended 31 March 2015	Year ended 31 March 2014
	£	£

Depreciation in excess of capital allowances	1,648	22,981
Other short term timing differences	-	1,540
Unutilised tax losses	3,808,624	3,745,123
Share-based payments	-	20,057
	3,810,272	3,789,701

16. Share capital

On 4 June 2015 the Company announced that it had joined PrimaryBid.com (www.primarybid.com), an online platform dedicated to equity crowdfunding for AIM-listed companies.

PrimaryBid.com provides a new channel for the Company to raise equity from investors, allowing investors to bid directly for new ordinary shares of 0.1p each in the Company at prices of their choosing, subject to certain limited restrictions.

PrimaryBid.com gives the Company ongoing access to an aggregated book of bids submitted by prospective investors, with the Company having full discretion as to whether or not to proceed with a share placing to raise capital through PrimaryBid.com.

Should the Company wish to proceed with a share placing this is done by issuing new shares, in order to satisfy any number of the bids presented through the PrimaryBid.com platform. Shares may only be issued to the extent that the Company has the requisite shareholder authorities to fulfil the issuance. Full details can be found on www.primarybid.com.

In June 2015, as a result of the Company joining PrimaryBid.com, the Company's existing 10 September 2013 Equity Financing Facility ('EFF') with Darwin Strategic Limited was cancelled.

EFF fee and warrant reserve

In consideration of Darwin agreeing to provide the EFF in September 2013 the Company agreed to:

(i) Pay a fee to Darwin amounting to approximately £35,000 by way of an issue of 3,414,635 fully paid Ordinary Shares, at a gross 1.025p per share. The contingent fee amounting to a maximum of £125,000 payable under the 7 November 2011 Equity Financing Facility was cancelled.

(ii) Enter into a new warrant agreement dated 10 September 2013 for the grant to Darwin of warrants to subscribe for up to ten million Ordinary Shares, such warrants to be exercisable at a price of 4.44 pence per share and to be exercisable at any time prior to the expiry of five years following the date of the new warrant agreement.

The warrants were measured at fair value at the date of grant using a Black-Scholes model, with the following assumptions:

Date of

grant

Exercise price

pence

Number of warrants

Share price at grant date

pence

Expected volatility

Risk free rate

Expected life

years

Fair value per share under warrant

pence

11-Sep-13

4.44

10,000,000

0.915

75%

0.79%

0.262

An expected dividend yield of 0% was used in the above valuation.

The assumption made for the expected life of the warrants is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.

The existing 10 September 2013 warrant agreement with Darwin continues to be in place under the new PrimaryBid.com arrangements.

The total fair value of the warrants, £26,200, has previously been held within prepayments and in the warrants reserve within equity. During the year ended 31 March 2015 the prepayment was released in full against share premium.

The warrants reserve will be released to share premium if the warrants are exercised. If the warrants lapse then the reserve will be transferred to retained earnings.

The £35,000 fee which was paid to Darwin in September 2013 by way of an issue of 3,414,635 fully paid Ordinary Shares, at a gross 1.025p per share, had initially been treated as a prepayment and it was expensed during the year ended 31 March 2015 as part of the share based payment charge.

Share re-organisation and reduction of capital

In August 2013, following a general meeting held on 15 July 2013, the Company undertook a share re-organisation and reduction of capital to facilitate the demerger of SiS (Science in Sport) Limited.

The demerger was effected by Provexis returning to Provexis shareholders capital in an amount equal to the market value of the ordinary shares of £1 each in the capital of SiS (Science in Sport) Limited as at 9 August 2013, the demerger effective date. The return of capital to Provexis shareholders was satisfied by the transfer by Provexis to Science in Sport plc of SiS (Science in Sport) Limited's ordinary shares of £1 each, and the allotment and issue of Science in Sport plc ordinary shares credited as fully paid to the holders of Provexis ordinary shares who were registered on the Provexis share register at 5.00 p.m. on 6 August 2013, the demerger record time, in accordance with the terms of the demerger agreement.

Full details of the demerger, share re-organisation and reduction of capital were provided on 28 June 2013 in a circular to shareholders and in an AIM admission document for Science in Sport plc. Further details of the demerger are provided in the Group's annual report and accounts for the year ended 31 March 2014.

The circular, AIM admission document and the Group's annual report and accounts for the year ended 31 March 2014 are available to download from the Company's website www.provexis.com.

Allotted, called up and fully paid	Ordinary 0.1p shares	Ordinary 0.1p shares
	£	number

At 31 March 2014	1,554,816	1,554,815,614
Issue on subscription - equity financing facility	30,030	30,030,330
At 31 March 2015	1,584,846	1,584,845,944

Allotted, called up and fully paid	Ordinary 0.1p shares	Deferred 0.9p shares	Science in Sport 0.1p Cancellation Shares	Redeemable £1 shares	Total
	number	number	number	number	number

At 31 March 2013	1,518,650,979	401,724,366	-	-	1,920,375,345
Demerger of SiS (Science in Sport) - issue redeemable shares	-	-	-	50,000	50,000
Demerger of SiS (Science in Sport) - issue Science in Sport Cancellation Shares	-	-	1,518,650,979	-	1,518,650,979
Demerger of SiS (Science in Sport) - redeem redeemable shares	-	-	-	(50,000)	(50,000)
Demerger of SiS (Science in Sport) - cancel deferred shares	-	(401,724,366)	-	-	(401,724,366)
Demerger of SiS (Science in Sport) - cancel Science in Sport Cancellation Shares	-	-	(1,518,650,979)	-	(1,518,650,979)
Issued on subscription - equity financing facility	31,000,000	-	-	-	31,000,000
Issued for equity financing facility fee	3,414,635	-	-	-	3,414,635
Issued on exercise of share options	1,750,000	-	-	-	1,750,000
At 31 March 2014	1,554,815,614	-	-	-	1,554,815,614

	Ordinary 0.1p shares	Deferred 0.9p shares	Science in Sport 0.1p Cancellation Shares	Redeemable £1 shares	Total
	£	£	£	£	£

At 31 March 2013	1,518,651	3,615,519	-	-	5,134,170
Demerger of SiS (Science in Sport) - issue redeemable shares	-	-	-	50,000	50,000
Demerger of SiS (Science in Sport) - issue Science in Sport Cancellation Shares	-	-	1,518,651	-	1,518,651
Demerger of SiS (Science in Sport) - redeem redeemable shares	-	-	-	(50,000)	(50,000)
Demerger of SiS (Science in Sport) - cancel deferred shares	-	(3,615,519)	-	-	(3,615,519)
Demerger of SiS (Science in Sport) - cancel Science in Sport Cancellation Shares	-	-	(1,518,651)	-	(1,518,651)
Issued on subscription - equity financing facility	31,000	-	-	-	31,000
Issued for equity financing facility fee	3,415	-	-	-	3,415
Issued on exercise of share options	1,750	-	-	-	1,750
At 31 March 2014	1,554,816	-	-	-	1,554,816

During the year ended 31 March 2015 the Company issued ordinary shares of 0.1p each as follows:

Date	Reason for issue	Shares issued
		£	Number
29.04.14	Share subscription - equity financing facility	7,000	7,000,000
15.12.14	Share subscription - equity financing facility	23,030	23,030,330
		30,030	30,030,330

During the year ended 31 March 2014 the Company issued ordinary shares of 0.1p each as follows:

Date	Reason for issue	Shares issued
		£	Number
17.09.13	Share subscription - equity financing facility	31,000	31,000,000
17.09.13	Share subscription - equity financing facility fee	3,415	3,414,635
22.11.13	Exercise of share options	1,750	1,750,000
		36,165	36,164,635

17. Share options

In June 2005 the Company adopted a new share option scheme for employees ('the Provexis 2005 share option scheme'). Under the scheme, options to purchase ordinary shares are granted by the Board of Directors, subject to the exercise price of the option being not less than the market value at the grant date. The options typically vest after a period of 3 years and the vesting schedule is subject to predetermined overall company selection criteria. In the event that the option holder's employment is terminated, the option may not be exercised unless the Board of Directors so permits. The options expire 10 years from the date of grant.

The Company undertook a reverse takeover of Provexis Natural Products Limited ('PNP', formerly Provexis Limited) in June 2005 through a share for share exchange. Prior to the takeover the Company and PNP had granted EMI options and unapproved options. Options granted by the Company prior to the takeover remain subject to the same terms as contained in the individual share option contracts under which they were originally granted. The PNP EMI options and unapproved options were rolled over into options over the Company's ordinary shares, and these replacement options remain subject to the same terms as contained in the individual PNP share option contracts under which they were originally granted.

Following the demerger of SiS (Science in Sport) Limited in August 2013 appropriate modifications were proposed to the exercise price of certain outstanding EMI and unapproved share option awards under Provexis' share option schemes. The proposed modifications were to reflect the reduction in value of Provexis which arose from the share re-organisation, reduction of capital and demerger of SiS (Science in Sport) Limited, calculated on a pro rata basis immediately after the demerger using the respective market values of Provexis plc and Science in Sport plc, net of Science in Sport plc's August 2013 placing ('the Demerger Modifications').

Details of the share re-organisation, reduction of capital, demerger of SiS (Science in Sport) Limited and proposed option Demerger Modifications were provided on 28 June 2013 in a circular to shareholders and in an AIM admission document for Science in Sport plc, which are available to download from the Company's website www.provexis.com.

As envisaged in the June 2013 circular to shareholders an advance assurance was sought from HMRC to approve the variation in the exercise price arising out of the reduction of capital and demerger for unexercised EMI options as at 9 August 2013, the demerger effective date. The advance assurance was not successful, and the Company remains in dialogue with HMRC on this issue. On 20 August 2014 it was agreed that the modifications proposed to the exercise price of certain outstanding awards under Provexis' share option schemes would take immediate effect.

On 3 September 2015 the Company granted a total of 2,500,000 new options over Ordinary Shares ('Options') under the Provexis 2005 share option scheme to Professor Asim Duttaroy, with an exercise price of 0.49 pence, being the closing mid-market price on 3 September 2015. The Options are exercisable between 3 and 10 years from date of grant and are subject to performance criteria, including share price appreciation.

Professor Asim Duttaroy was the original inventor of Fruitflow® and he serves on the Company's Scientific Advisory Board. On 18 November 2014 the Company announced it had signed a collaboration agreement with the University of Oslo to undertake further research into the relationship between Fruitflow® and blood pressure regulation, with the University's collaboration work to be led by Professor Duttaroy. The Company believes the grant of these new Options will closely align the interests of Professor Duttaroy with those of shareholders.

Following the issue of the new Options the total number of Ordinary Shares under option which could be issued if all of the performance criteria are met are 118,617,620 Ordinary Shares.

The fair values of the options granted during the year were estimated at the date of grant in accordance with IFRS 2, using a Black-Scholes model. Where options have been approved but not formally granted and optionholders have provided services in advance of the grant of options a charge is recognised using an estimated fair value based on the period end share price.

At 31 March 2015 the number of ordinary shares subject to options granted over the 2005 and prior option schemes were:

EMI options

	31 March 2015				31 March 2014
	Weighted average exercise price (pence)	Weighted average share price at date of exercise (pence)	Number	Weighted average exercise price (pence)	Weighted average share price at date of exercise (pence)	Number

Outstanding at the beginning of the year	0.78	-	58,494,665	1.44	-	55,802,021
Granted during the year	-	-	-	0.97	-	20,635,000
Exercised during the year	-	-	-	0.90	1.98	(1,750,000)
Cancelled during the year	0.90	-	(2,416,575)	2.56	-	(16,192,356)
Outstanding at the end of the year	0.77	-	56,078,090	0.78	-	58,494,665

The exercise price of EMI options outstanding at the end of the year ranged between 0.59p and 1.85p (2014: 0.59p and 1.85p) and their weighted average contractual life was 5.3 years (2014: 6.0 years).

Of the total number of EMI options outstanding at the end of the year, 49,078,090 (2014: 49,844,675) had vested and were exercisable at the end of the year. Their weighted average exercise price was 0.74 pence (2014: 0.71 pence).

Unapproved options

	31 March 2015		31 March 2014
	Weighted average exercise price (pence)	Number	Weighted average exercise price (pence)	Number

Outstanding at the beginning of the year	1.30	52,145,845	2.30	34,269,627
Granted during the year	0.67	10,000,000	0.97	19,365,000
Cancelled during the year	-	-	3.20	(1,488,782)
Outstanding at the end of the year	1.20	62,145,845	1.30	52,145,845

The exercise price of unapproved options outstanding at the end of the year ranged between 0.59p and 1.85p (2014: 0.59p and 1.85p) and their weighted average contractual life was 6.9 years (2014: 7.3 years).

Of the total number of unapproved options outstanding at the end of the year, 45,145,845 (2014: 38,795,835) had vested and were exercisable at the end of the year. Their weighted average exercise price was 1.35 pence (2014: 1.27 pence).

Grant of options

The fair values of the options have been estimated at the date of grant using a Black-Scholes model, using the following assumptions:

Tranche	Date of grant	Exercise price pence	Number of options	Share price at grant date pence	Expected volatility	Risk free rate	Expected life years	Fair value per share under option pence

1	26-Aug-08	0.9	44,166,575	0.87	65%	4.45%	10	0.585
2	17-Jun-11	2.8	51,300,000	2.00	88%	4.48%	10	1.17
3	27-Jun-13	1.475	40,000,000	1.475	88%	0.79%	10	0.785
4	17-Nov-14	0.67	10,000,000	0.67	74%	0.94%	10	0.515

The fair value of the Demerger Modifications made to the exercise price of certain outstanding awards under Provexis' share option schemes has been estimated in accordance with IFRS 2, using a Black-Scholes model. The fair value of the Demerger Modifications is charged to the statement of comprehensive income over the vesting period as part of the share based payment charge.

An expected dividend yield of 0% has been used in all of the above valuations.

The expected life of the options is based on historical data and is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.

The total share based payment charge for the year relating to employee share based payment plans was £54,375 (2014: £391,191) all of which related to equity settled share-based payment transactions. The Group's share based payment charge for the year ended 31 March 2015 totalling £89,375 included an additional £35,000 share based payment charge (2014: £Nil) in respect of a fee which was paid to Darwin in September 2013 by way of an issue of Ordinary Shares, as further detailed in note 16.

18. Reserves

	Share premium reserve	Warrant reserve	Merger reserve	Retained earnings	Total attributable to equity holders of the parent	Non-controlling interest	Total reserves
	£	£	£	£	£	£	£


At 31 March 2015	16,298,043	26,200	6,599,174	(23,886,736)	(963,319)	(375,627)	(1,338,946)


At 31 March 2014	16,183,870	26,200	6,599,174	(23,505,513)	(696,269)	(323,472)	(1,019,741)

Details of movements in reserves are provided as part of the consolidated statement of changes in equity.

The following describes the nature and purpose of each reserve within total equity:

Share capital	Amount subscribed for share capital at nominal value.
Share premium	Amount subscribed for share capital in excess of nominal value.
Warrant reserve	The warrant reserve represents warrants issued as part of the Equity Financing Facility (see note 16).
Merger reserve	The merger reserve arose on the reverse takeover in 2005 of Provexis Natural Products Limited (formerly Provexis Limited) by Provexis plc through a share for share exchange and on the issue of shares for the acquisition of SiS (Science in Sport) Limited in 2011.
Retained earnings	Cumulative net gains and losses recognised in the consolidated statement of comprehensive income.

19. Pension costs

The pension charge represents contributions payable by the Group to independently administered funds which for continuing operations during the year ended 31 March 2015 amounted to £Nil (2014: £7,624). Pension contributions payable but not yet paid at 31 March 2015 totalled £3,871, in respect of pension contribution entitlements where employees had not yet provided details of the funds to which the contributions should be made (2014: £3,871).

20. Operating lease commitments

Future minimum rentals payable under non-cancellable operating leases are as follows:

	31 March 2015	31 March 2014
	£	£
Due within 1 year	-	8,151
	-	8,151

Operating lease payments primarily represent rentals that were payable by the Group for various offices. The leases had various terms, escalation clauses and renewal rights typical of lease agreements for the class of asset.

21. Related party transactions

On 1 June 2010 the Company announced a long-term Alliance Agreement with DSM Nutritional Products, which has seen the Company collaborate with DSM to develop Fruitflow® in all major global markets. DSM has invested substantially in the manufacture, technology development, marketing and sale of Fruitflow® since the Alliance Agreement was signed. Provexis continues to contribute scientific expertise and is collaborating in areas such as cost of goods optimisation and regulatory matters. The financial model is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales.

The Company is working closely with DSM in various areas of the project, and in June 2015 it was announced that the Company had agreed significantly enhanced financial terms for its long-term Alliance Agreement with DSM, involving a reduction in the fixed level of overhead deduction from sales which permanently decreased with effect from 1 January 2015, backdated, thus increasing the profit share payable to the Company. It is not possible to determine the financial impact of the Alliance Agreement at this time.

DSM is classified as a related party of the Group in accordance with IAS 24 as it holds shares in the Group. Further, K Rietveld is a director of the Company, and a senior employee of DSM. The directors of Provexis (the 'Directors'), having consulted with Cenkos Securities Limited ('Cenkos Securities'), the Company's nominated adviser, consider that the terms of the Alliance Agreement are fair and reasonable insofar as Provexis's shareholders are concerned. In providing advice to the Directors, Cenkos Securities has taken into account the Directors' commercial assessments.

Revenue recognised by the Group under agreements with DSM amounted to £37,124 (2014: £3,967). At 31 March 2015 the Group was owed £Nil (2014: £Nil) by DSM.

Key management compensation

The directors represent the key management personnel. Details of their compensation and share options are given in note 6.

22. Post balance sheet events

On 4 June 2015 the Group also announced that it had joined PrimaryBid.com (www.primarybid.com), an online platform dedicated to equity crowdfunding for AIM-listed companies which is further detailed in note 16. The Group confirmed on 4 June 2015 that as a result of the Company joining PrimaryBid.com the Company's existing 10 September 2013 Equity Financing Facility ('EFF') with Darwin Strategic Limited had been cancelled.

This information is provided by RNS

The company news service from the London Stock Exchange

END

FR UORURVOAKRUR

Companies

Provexis (PXS)

Friday, 20th December 2024

COMPANIES COVERED:

SRP NMT RPI

Serco extends Thursday’s gains as upbeat mood prevails and Raspberry Pi also advances off the back of stake building news, but Neometals under pressure as it plans cancellation of AIM listing to focus on ASX.

Full Archive

UK 100

Latest directors dealings

1 day ago The Renewables Infrastructure Group Limited
1 day ago The Renewables Infrastructure Group Limited
1 day ago Smurfit Westrock (DI)
1 day ago Menhaden Resource Efficiency
1 day ago BP

All directors dealings today